BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2019 Earnings Results

BioCryst Pharmaceuticals Misses on EPS, Stock Up 1.56%

The earnings report indicates that BioCryst Pharmaceuticals is still facing challenges, as evidenced by the EPS miss. However, the stock rose by 1.56%, suggesting that investors may be optimistic about the company's long-term strategy and pipeline developments. The lack of revenue figures and guidance leaves some uncertainty, but the positive stock reaction indicates a degree of investor confidence.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.28	N/A	-5.46%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on pipeline development and is optimistic about future prospects. They acknowledged the challenges but emphasized their commitment to growth.

Management highlighted ongoing efforts to advance their pipeline.

They expressed confidence in their long-term strategy despite the current EPS miss.

BioCryst Pharmaceuticals Misses on EPS, Stock Up 1.56%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

BioCryst Pharmaceuticals Misses on EPS, Stock Up 1.56%

Key numbers

Management commentary